(Q28296706)

English

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Belinda Pinto Simoes

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

R Buhmann

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

M Stanglmaier

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

T Yang

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

M Faltin

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

D Bund

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

H Lindhofer

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

H-J Kolb

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

0 references

publication date

13 October 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Bone Marrow Transplantation

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

43

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

383-397

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Two new trifunctional antibodies for the therapy of human malignant melanoma

1 reference

https://api.crossref.org/works/10.1038/BMT.2008.323

20 April 2017

Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

The graft-versus-lymphoma effect: clinical review and future opportunities

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

From the bench to the bedside: ways to improve rituximab efficacy.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

Bispecific antibodies in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

A revival of bispecific antibodies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

Rituximab therapy in malignant lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

Immunotherapy of malignant ascites with trifunctional antibodies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

21 January 2018

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

7 January 2021

based on heuristic

inferred from DOI database lookup

Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

7 January 2021

based on heuristic

inferred from DOI database lookup

Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

7 January 2021

based on heuristic

inferred from DOI database lookup

Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group fo

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

7 January 2021

based on heuristic

inferred from DOI database lookup

Bispecific antibody fragments with CD20 X CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

7 January 2021

based on heuristic

inferred from DOI database lookup

The immunopathophysiology of acute graft-versus-host-disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.323

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BMT.2008.323

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850012%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

ResearchGate publication ID

0 references

Springer Nature article ID

10.1038/bmt.2008.323

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28296706&oldid=1834262690"